Ovarian Epithelial Carcinoma

A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.

Also Known As:

Carcinoma, Ovarian Epithelial; Epithelial Ovarian Cancer; Epithelial Ovarian Carcinoma; Ovarian Cancer, Epithelial; Ovarian Epithelial Cancer; Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian; Epithelial Carcinoma, Ovarian; Epithelial Ovarian Cancers; Epithelial Ovarian Carcinomas; Ovarian Carcinoma, Epithelial; Ovarian Epithelial Cancers; Ovarian Epithelial Carcinomas

Networked: 7931 relevant articles (436 outcomes, 1729 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Ovarian Neoplasms (Ovarian Cancer)
3.	Carcinoma (Carcinomatosis)
4.	Neoplasm Metastasis (Metastasis)
5.	Endometrial Neoplasms (Endometrial Cancer)

Experts

1.	Sehouli, Jalid: 58 articles (01/2022 - 03/2003)
2.	Sood, Anil K: 54 articles (11/2021 - 10/2002)
3.	Odunsi, Kunle: 47 articles (10/2021 - 09/2002)
4.	Scambia, Giovanni: 46 articles (08/2022 - 07/2003)
5.	Berchuck, Andrew: 41 articles (01/2022 - 08/2004)
6.	Karlan, Beth Y: 41 articles (01/2020 - 02/2002)
7.	Coleman, Robert L: 40 articles (11/2021 - 01/2002)
8.	Li, Yan: 37 articles (12/2022 - 04/2003)
9.	Schildkraut, Joellen M: 37 articles (01/2022 - 01/2002)
10.	Vergote, Ignace: 37 articles (01/2022 - 02/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ovarian Epithelial Carcinoma:

1.	PlatinumIBA 01/01/2016 - "The best treatment for relapsed platinum sensitive epithelial ovarian cancer (EOC) is controversial. " 02/01/2015 - "This study confirmed that laparoscopy could be effective for the selection of platinum-sensitive recurrent epithelial ovarian cancer patients suitable for complete cytoreduction." 12/01/2021 - "To identify clinicopathologic factors predictive of early relapse (platinum-free interval (PFI) of ≤6 months) in advanced epithelial ovarian cancer (EOC) in first-line treatment, and to develop and internally validate risk prediction models for early relapse. " 01/04/2021 - "Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer." 11/01/2023 - "To study the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet count in patients with platinum-sensitive recurrent epithelial ovarian cancer (PS-ROC). "
2.	Paclitaxel (Taxol)FDA LinkGeneric 01/01/1997 - "The aim of this study was to evaluate the efficacy of high-dose paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. " 10/01/2019 - "In this study, we have evaluated the synergistic efficacy of TAM repolarization and intraperitoneal paclitaxel in epithelial ovarian cancers. " 07/26/2016 - "Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations." 11/01/2018 - "Our study demonstrated that c-Src contributed to hypoxic microenvironment-rendered paclitaxel resistance in human epithelial ovarian cancer cells by G2/M phase arrest deterioration, and through c-Src suppression, FV-429 was capable of reversing the resistance by blocking c-Src/Stat3/HIF-1α pathway." 11/01/2013 - "The aim of the present study was to assess whether paclitaxel-resistant epithelial ovarian carcinoma is capable of generating cells with CSC-like properties. "
3.	Carboplatin (JM8)FDA LinkGeneric 11/01/1999 - "The aim of this study was to evaluate the efficacy of 51Cr-EDTA clearance to tailor the carboplatin dose in two different therapeutic regimens of advanced epithelial ovarian cancer. " 09/01/2017 - "The purpose of the current study was to explore the carboplatin‑induced sequential changes in gene expression and screen out key genes, which were associated with effects of carboplatin on epithelial ovarian cancer (EOC). " 01/01/2006 - "One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study." 07/01/1998 - "Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. " 03/01/1993 - "Two hundred fifty-four patients with advanced epithelial ovarian cancer (stages IIB to IV) were entered onto a study of five monthly courses of 400 mg/m2 of carboplatin. "
4.	Cisplatin (Platino)FDA LinkGeneric 07/01/2002 - "Although cisplatin derivatives are first-line chemotherapeutic agents for the treatment of epithelial ovarian cancer, chemoresistance remains a major hurdle to successful therapy and the molecular mechanisms involved are poorly understood. " 12/01/2017 - "The algorithm was then used to propose the system-oriented strategy to search drugs effective in limiting the growth rate of the cisplatin-resistant A2780 epithelial ovarian cancer cell. " 09/08/2023 - "The aim of this study was to determine the value of targeting PAPSS1 as a cisplatin modulator in epithelial ovarian cancer (EOC). " 10/01/2021 - "Our study showed that CXCR4 and RIF1expression levels are not associated only with poor prognostic features of epithelial ovarian cancer but also with its chemoresistance to cisplatin, and consequently, with worse overall survival and progression free survival." 10/01/2020 - "Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort."
5.	Bevacizumab (Avastin)FDA Link 09/01/2013 - "The purpose of this study was to compare the distribution of the first site of recurrence in patients with epithelial ovarian cancer (EOC) who received first-line treatment with bevacizumab compared with patients who did not receive bevacizumab. " 01/01/2022 - "Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer." 01/01/2014 - "Bevacizumab (Bev) is associated with improved progression-free survival in advanced epithelial ovarian cancer. " 03/01/2005 - "Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated." 01/01/2023 - "We assessed the evolution of treatment patterns and survival of patients with advanced epithelial ovarian cancer with specific attention to changes in survival after introducing bevacizumab. "
6.	Biomarkers (Surrogate Marker)IBA 01/01/2018 - "We investigated whether PFS is a good surrogate endpoint for OS in trials of first-line treatment for epithelial ovarian cancer (EOC), and whether this relationship has changed with the introduction of new treatment types. " 08/15/2012 - "Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer." 01/01/2022 - "CDC20 is a novel biomarker for improved clinical predictions in epithelial ovarian cancer." 01/01/2022 - "CA125 is the gold standard serum biomarker for monitoring patients with epithelial ovarian cancer (EOC). " 01/01/2019 - "The identification of predictive biomarkers for the first-line treatment of epithelial ovarian cancer (EOC) remains a challenge. "
7.	Topotecan (Hycamtin)FDA LinkGeneric 10/15/2002 - "Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma." 01/01/2007 - "The objective of this study was to investigate the effectiveness and toxicity of weekly topotecan in patients with recurrent epithelial ovarian cancer. " 12/01/2004 - "Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer." 10/15/2002 - "The objective of the study was to evaluate the treatment results and toxicity of a low-dose topotecan regimen as second-line treatment for patients with epithelial ovarian carcinoma. " 01/01/2002 - "A multicentre, randomised study was carried out in Europe, South Africa and North America to compare the activity and tolerability of oral versus intravenous (i.v.) topotecan in patients with relapsed epithelial ovarian cancer. "
8.	Gemcitabine FDA Link 01/01/2014 - "To study the response rate (RR), progression-free survival (PFS) and toxicity profiles of recurrent epithelial ovarian cancer (EOC) patients treated with gemcitabine. " 09/01/2001 - "This study assessed the activity of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. " 09/01/2001 - "Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer." 01/01/2016 - "We present a 63-year-old female with recurrent epithelial ovarian cancer who developed SCLE after administration of gemcitabine. " 01/01/2014 - "Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients."
9.	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/01/2020 - "Conclusion: PARP inhibitors are an effective and well-tolerated treatment for patients with advanced-stage epithelial ovarian cancer." 01/01/2023 - "The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADP-ribose) polymerase inhibitors into clinical practice. " 01/01/2022 - "With the common use of poly ADP-ribose polymerase inhibitors (PARPi) for the man-agement of epithelial ovarian cancer (EOC) across the treatment life cycle, there is a critical need for the development of functional tests, as a complementary to genomic assays, in the study of PARPi sensitivity and resistance. " 01/01/2021 - "We searched MEDLINE, EMBASE, the Cochrane Library, Web of Science and relevant clinical research registry platforms on October 1, 2019, and included randomized controlled trials (RCTs) that compared PARP inhibitors with placebo in women (aged ≥ 18 years) with newly diagnosed epithelial ovarian cancer. " 01/01/2018 - "A comprehensive PUBMED literature review was conducted to identify all published phase 2 and phase 3 clinical trials involving PARP inhibitors in advanced epithelial ovarian cancer. "
10.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/01/1991 - "We treated 7 patients with advanced or recurrent epithelial ovarian cancers, using the adoptive transfer of these tumor-infiltrating lymphocytes (TILs) following a single i.v. injection of cyclophosphamide. " 06/01/1990 - "From 1 September 1981 to 1 January 1987, 118 patients with FIGO Stage IB, IC, IIA, IIB, and IIC epithelial ovarian cancer were randomized to abdominal irradiation or pelvic irradiation + cyclophosphamide. " 10/01/2010 - "We reassessed the usefulness of oral cyclophosphamide (CPA) salvage therapy for heavily pretreated patients with recurrent epithelial ovarian cancer. " 10/01/2010 - "Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer." 12/01/1985 - "A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 04/01/2007 - "The most effective treatment for epithelial ovarian cancer is the combination of surgical operation and chemotherapy. " 01/01/2000 - "To investigate the best first-line chemotherapy regimen for the treatment of advanced epithelial ovarian cancer (AEOC), the efficacy of three chemotherapy regimens for treatment of the patients with AEOC in our hospital during Jan. " 01/01/2004 - "A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?" 03/01/2015 - "Surgery and chemotherapy are the standard of care for epithelial ovarian cancer, and it is well established that survival outcomes are improved when the surgery results in no or optimal (less than 1 cm) residual disease. " 03/01/2002 - "The majority of patients with epithelial ovarian cancer (EOC) who achieve a complete remission with front-line chemotherapy develop recurrent disease. "
2.	Therapeutics 01/01/2009 - "Epithelial ovarian cancer is a deadly disease for which improved outcomes could be achieved by successful early detection and enhanced understanding of molecular pathogenesis that leads to improved therapies. " 01/01/2018 - ": These findings offer preclinical evidence of the therapeutic efficacy of a novel targeted antibody therapy against deadly epithelial ovarian cancers. " 07/05/2016 - "Understanding the biology and molecular pathogenesis of ovarian epithelial cancer (EOC) is key to developing improved diagnostic and prognostic indicators and effective therapies. " 02/01/2014 - "This study was aimed to evaluate the clinical efficacy of maintenance therapy of CIK cells in patients with advanced epithelial ovarian cancer after first-line treatment. " 01/01/2019 - "Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis."
3.	Cytoreduction Surgical Procedures 11/01/2003 - "To increase the optimal rate of secondary cytoreductive surgery in these patients is helpful for improving the prognosis of recurrent epithelial ovarian cancer patients. " 01/01/2022 - "Cytoreductive surgery is the mainstay of treatment for high-grade epithelial ovarian cancer. " 01/01/2015 - "Secondary cytoreductive surgery (SCS) is reported to be beneficial for patients with recurrent epithelial ovarian carcinoma (EOC). " 12/01/2005 - "Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients." 02/15/2007 - "The objective of this study was to evaluate the role of secondary cytoreductive surgery in the outcome of patients who had recurrent epithelial ovarian carcinoma that was limited to <or=5 recurrence sites within the abdomen or pelvis on preoperative imaging studies and attempt to define selection criteria associated with improved survival, with specific attention to the number of lesions suspicious for recurrent disease. "
4.	Neoadjuvant Therapy 01/01/2017 - "To assess whether neoadjuvant chemotherapy (NACT) is superior to primary debulking surgery (PDS) with regard to optimal cytoreduction, peri-operative morbidity, mortality, and quality of life (QOL) in advanced epithelial ovarian cancer (EOC). " 09/01/2001 - "A survey addressing the definition of "optimal" cytoreduction, the use of neoadjuvant chemotherapy, disease sites precluding optimal cytoreduction, reasons optimal cytoreduction or cytoreduction to a visibly disease-free outcome is or is not accomplished, the use of 15 specific operative procedures, and attitude toward postfellowship training in the surgical management of advanced stage epithelial ovarian cancer was mailed to candidate and full members of the Society of Gynecologic Oncologists. " 01/01/2015 - "Neoadjuvant chemotherapy, followed by surgical cytoreduction is a promising treatment strategy for the management of advanced epithelial ovarian cancers." 04/01/2021 - "We evaluated the effectiveness, safety and efficacy of robotic interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC) treated with neoadjuvant chemotherapy (NACT). " 06/01/2023 - "Three randomized controlled trials have resulted in extremely extensive application of the strategy of using neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for patients with advanced epithelial ovarian cancer in Japan. "
5.	Hyperthermic Intraperitoneal Chemotherapy 11/01/2023 - "The consolidation HIPEC demonstrated a significant improvement in 10-year PFS but not OS, with acceptable toxicity in patients with primary epithelial ovarian cancer. " 01/01/2011 - "Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer." 11/01/2023 - "We aimed to evaluate the long-term efficacy of consolidation hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with primary epithelial ovarian cancer. " 12/15/2020 - "An improvement in survival without increasing perioperative morbidity in patients with advanced epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) has been recently demonstrated in a randomized controlled trial. " 01/01/2019 - "Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis."